Related Experiment Videos
Pharmacogenomics: road to anticancer therapeutics nirvana?
Apurva A Desai1, Federico Innocenti, Mark J Ratain
1Department of Medicine, The University of Chicago, Chicago, IL, USA.
Oncogene
|October 7, 2003
Summary
Pharmacogenomics helps predict patient responses to cancer drugs by studying genetic variations. This approach aims to personalize treatments, improving efficacy and reducing toxicity for better patient outcomes.
Area of Science:
- Oncology
- Pharmacogenomics
- Genetics
Background:
- Interindividual variability in anticancer drug response and toxicity is a significant clinical challenge.
- Unpredictable drug responses are especially dangerous for anticancer agents with narrow therapeutic indices.
- Pharmacogenomics seeks to understand the genetic basis of these differences to enable individualized cancer treatments.
Purpose of the Study:
- To review the role of pharmacogenomics in anticancer therapeutics.
- To highlight how genetic variants influence the efficacy and toxicity of cancer treatments.
- To exemplify the impact of pharmacogenomics using specific gene variants.
Main Methods:
- Review of existing literature on pharmacogenomics in oncology.
- Analysis of genetic polymorphisms in drug-metabolizing enzymes, DNA repair genes, and drug targets.
- Focus on specific examples including UGT1A1, TS, and EGFR genetic variants.
Main Results:
- Genetic polymorphisms in key genes demonstrably affect anticancer drug toxicity and efficacy.
- Variants in UGT1A1, TS, and EGFR are shown to influence treatment outcomes.
- Pharmacogenomic data provides a basis for predicting and managing interindividual drug responses.
Conclusions:
- Pharmacogenomics holds significant potential for optimizing anticancer therapy.
- Understanding genetic variations can lead to more individualized and effective cancer treatment strategies.
- Personalized medicine approaches guided by pharmacogenomics can improve patient safety and treatment success in oncology.